Roble, Belko & Company, Inc Aeglea Bio Therapeutics, Inc. Transaction History

Roble, Belko & Company, Inc

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Nov 13, 2019	SELL	$6.42 - $9.0 $642 - $900	-100 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$6.1 - $8.78 $610 - $877	100 New	100 $1,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Roble, Belko & Company, Inc, based on Form 13F filings with the SEC.

Stay updated on Roble, Belko & Company, Inc with notifications on news.